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Abstract: Nowadays, tissue engineering is described as an interdisciplinary field that combines 
engineering principles and life sciences to generate implantable devices to repair, restore and/or 
improve functions of injured tissues. Such devices are designed to induce the interaction and 
integration of tissue and cells within the implantable matrices and are manufactured to meet the 
appropriate physical, mechanical and physiological local demands. Biodegradable constructs based 
on polymeric fibers are desirable for tissue engineering due to their large surface area, 
interconnectivity, open pore structure, and controlled mechanical strength. Additionally, 
biodegradable constructs are also very sought-out for biomolecule delivery systems with a target-
directed action. In the present review, we explore the properties of some of the most common 
biodegradable polymers used in tissue engineering applications and biomolecule delivery systems 
and highlight their most important uses. 
Keywords: regenerative medicine; tissue engineering; micro- and nanofibers; soft and hard tissue 
substitution; local and systemic biomolecule delivery 
 
1. Introduction 
For many years, the use of artificial fibrous structures was restricted to applications in clothing 
and decoration. In the past century though, fiber constructs made breakthroughs in engineering with 
applications in filtration, composite fabrication, energy systems and microfluids [1]. More recently, 
fibers manufactured as mono- or multi-filaments entered the field of medicine. 
Biotextiles based on natural and synthetic fibers are very common in tissue engineering. They 
are defined as ‘‘structures composed of textile fibers and designed for uses in a specific biological 
environment (e.g., surgical implant), where their performance depends on their interactions with 
cells and biological fluids as measured in terms of biocompatibility and biostability’’ [2]. The 
applications of biotextiles cover a large spectrum; they have been used in heart valve swing rings, 
vascular grafts, hernia repair meshes, percutaneous access devices, wound dressings, delivery 
systems, etc. [3]. In many of these cases, biotextiles are processed in the form of fibrous structures 
with a large surface area and adequate chemistry, high and uniform porosity and pore 
interconnectivity, resembling the fibrous architecture of the extracellular matrix and, in this way, 
enabling cell adhesion and migration, vascularization and nutrients transport [4,5]. 
Manufacture of biocomposites can be achieved by several processing techniques, which allow 
biotextiles, presented in the form of loose fibers, nonwoven mats, aligned yarns or woven fabrics, to 
attain specific mechanical properties in the final product. Other factors influencing their properties 
are the type of natural or synthetic fiber, the chemical compatibility between the fiber and matrix 
phases, the corresponding surface energies and the properties of the interface. Furthermore, fiber 
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separation and extraction processes play a determinant role in the quality, yield and structure of the 
final product [5]. 
Polymer fibers used in tissue engineering applications and biomolecule delivery systems can be 
fashioned using a variety of additive manufacturing techniques, such as 3D printing. However, the 
most common are the spinning methods: wet spinning, dry spinning, melt spinning, gel spinning 
and electrospinning (co-spinning and co-axial spinning being the most recurrent for delivery 
systems) [1,6]. All of these are based on the extrusion of polymer melts or solutions through a 
spinneret under controlled operating, solution and environment conditions. During fiber processing, 
using biodegradable polymers, additional monitoring is required to prevent polymers from 
undergoing degradation. This is particularly important during melt processing due to the high 
temperatures [7]. Constructs based on biotextiles should be capable of restoring the local 
biomechanical functions while maintaining a controlled degradation rate that matches the tissue 
healing or regeneration processes [3]. Thus, fabrication of fibrous devices that support and instigate 
tissue regeneration using biodegradable polymers endowed with biocompatibility and biostability 
properties is recommended for successful outcomes. For regeneration purposes, it is also necessary 
to select the appropriate cell sources. Mesenchymal stem cells are frequently selected due to their 
unique capacity of differentiation into one or several types of specialized cells [8]. In biomolecule 
delivery systems, the compatibility of the drug (antibiotic, growth factors, antimicrobial peptide, 
essential oil, plant extract, etc.) with the polymer is crucial for a successful outcome [5,9,10]. Still, 
challenges remain on this front due to the degradation or denaturation of the biological molecules 
when combined with organic solvents. 
Previous publications focused on the advances in the manufacturing of biofunctional fibers [11] 
and on the development of nanofibrous scaffolds by electrospinning [12], natural-fiber reinforced 
biocomposites [5] and cellulose-based electrospun scaffolds for wound healing [13], as well as 
possible tridimensional fibrous structures for flat bone regeneration [14] and even the use of 
electrochemically aligned collagen threads in the form of scaffolds to repair critical infraspinatus 
tendon defects [15]. The present work addresses these issues and the applications and advantages 
introduced by biotextiles in tissue engineering and controlled drug release. In fact, here, the 
properties of the most commonly used natural and synthetic biodegradable polymers in tissue 
engineering and biomolecule delivery systems and their processing technologies are enumerated. 
Development and optimization of biodegradable fibers and the respective processing conditions are 
discussed in light of their final application, and important outcomes introduced by such systems are 
reviewed. Finally, examples of biodegradable biotextiles applied in soft and hard tissue repair and 
substitution and in biomolecule-controlled delivery applications are also highlighted. 
2. Biodegradable Polymers 
For many years now, biodegradable polymers (hydrolytically and enzymatically degraded) 
have been used for biomedical applications with an emphasis on tissue engineering and biomolecule 
delivery systems for regenerative medicine. It is predicted that in the next few years, they will gain 
an even more important status by replacing biostable temporary therapeutic devices used only for 
substitution. In light of the ethical and technical issues that surround the latter, which most of the 
time require revision surgeries, the use of biodegradable polymers, capable of stimulating the body 
to repair and regenerate damaged tissues, is desirable [16,17]. 
In regenerative medicine, biodegradable polymers are required to exhibit specific properties: (1) 
they do not instigate or induce a toxic response upon implantation; (2) they present an acceptable 
shelf-life; (3) they degrade at a rate that matches the healing or regeneration processes; (4) they 
possess appropriated mechanical properties that vary with degradation in a proportion compatible 
with the healing or regeneration processes; (5) they do not produce toxic degradation by-products; 
and (6) they are permeable and easily processed for the intended application [18]. It should also be 
noticed that the chemical, physical, mechanical and biological properties of biodegradable polymers 
may alter during degradation and thus should be monitored over time [16]. 
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Degradation of synthetic and natural polymers requires cleavage of bonds sensitive to 
hydrolytic or enzymatic action. Synthetic polymers are characterized by predictable properties and a 
certain uniformity in site-to-site and patient-to-patient outcomes. They can be processed with specific 
properties that respond to local demands or application requirements and are most of the time 
hydrolytically degraded. Compared to polymers susceptible to enzymatic degradation, those 
hydrolytically degraded are preferred due to the predictability in body response after implantation 
[16]. Table 1 provides a list of some of the most common synthetic biodegradable polymers used in 
tissue engineering and their inherent properties, including average degradation rates (time to 
complete resorption). 
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Table 1. Synthetic biodegradable polymers used in tissue engineering: Physical, mechanical and degradation properties. 
Polymer Melting Point 
(°C) 
Glass Transition 
Temperature (°C) 
Tensile Modulus 
(Gpa) 
Elongation 
(%) 
Degradation Time 
(months) 
Reference 
Polycaprolactone (PCL) 58–63 (−65)–(−60) 0.2–0.4 300–1000 >24 [19] 
Poly(glycolic acid) (PGA) 220–233 35–40 6.0–7.0 1.5–20 6–12 [19] 
Poly(lactic-co-glycolic acid) 
(PLGA) Amorphous 45–55 1.4–2.8 3–10 1–12 (adjustable) [20] 
Poly(lactic acid) (PLA) 150–162 45–60 0.4–3.5 2.5–6 >24 [21] 
Poly (L/D-lactide) (PLLA or 
PDLA) 
170–200 55–65 2.7–4.1 3–10 >24 [21] 
Poly (DL-lactide) (PDLLA) Amorphous 50–60 1–3.5 2–10 12–16 [21] 
Polydioxanone (PDO) N/A −10–0 1.5 N/A 6–12 [19] 
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2.1. Synthetic-Origin Polymers 
Several synthetic polymers have been fabricated and explored over the years, mostly by 
polymerization techniques. The majority provide unique and important physical and chemical 
properties, and some of them are applied in the design of scaffolds for drug delivery systems and 
tissue engineering purposes. There are different kinds of synthetic biodegradable polymers, such as 
polylactic acid (PLA), polyglycolic acid (PGA), poly(ε-caprolactone) (PCL), which have 
demonstrated exceptional biocompatible features such as degrading in vivo into non-toxic 
components at controlled rates and to displaying good mechanical properties [22]. 
2.1.1. PCL 
PCL is a hydrophobic, semi-crystalline, linear resorbable aliphatic polyester obtained by either 
ring-opening polymerization of caprolactone or via free-radical ring-opening polymerization of 2-
methylene-1-3-dioxepane [23]. Its biodegradation is associated with its aliphatic ester linkage 
susceptibility to hydrolysis. The good solubility, low melting point and compatibility with other 
polymers make PCL exceptionally great for biomedical applications [24]. 
2.1.2. PGA 
Poly(glycolic acid) (PGA) is a highly crystalline, biocompatible polyester with good mechanical 
features and degradation profile, low solubility in organic solvents and excellent fiber-forming ability 
due to its high tensile modulus [25,26]. PGA was used in the production of the first synthetic, 
absorbable surgical suture [27]. However, because of its hydrophilic nature and quick water uptake, 
its mechanical strength may be lost after a period of 2 to 4 weeks post-implantation. Since then, PGA 
has been used for a variety of purposes, including bone fixation devices, biomolecule carriers and 
scaffolds matrices for tissue regeneration [19,25,26]. 
2.1.3. PLA 
PLA is a biodegradable, aliphatic polyester derived from lactic acid. It is a versatile polymer 
made of renewable materials, i.e., corn starch or sugar cane, that can be fermented into lactic acid and 
prepared via cyclic dilactone, lactide, ring-opening polymerization. During this process, PLA 
enhances its thermal stability, stiffness and strength and reduces residual monomer content [28]. PLA 
is more hydrophobic than PGA due to the presence of an extra methyl group in lactic acid [29]. 
2.1.4. PLGA 
By varying the ratios between its copolymers PGA and PLA, the poly(lactic-co-glycolic acid) 
(PLGA) co-polymer offers a wide range of degradation rates. Its degradation kinetics is governed by 
both the hydrophobic/hydrophilic balance and crystallinity, which makes PLGA particularly 
desirable for tissue engineering applications due to its excellent biocompatibility and biodegradable 
properties [20,30]. 
2.1.5. PDLA, PLLA and PDLLA 
PLA exists in two stereoisomeric forms, giving rise to PDLA and PLLA, two stereoregular 
polymers, and PDLLA, a racemic polymer obtained from the mixture of D- and L-lactic acid (Figure 
1). PDLLA is an amorphous polymer commonly used for drug delivery due to its ability to disperse 
homogeneously the active species within a monophasic matrix. As semi-crystalline polymers, both 
PDLA and PLLA are favored for applications in orthopedics where high mechanical strength and 
toughness are necessary [21,31,32]. 
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Figure 1. Chemical structure of PGA, PLA, PLGA and the enantiomers D- and L-lactide. 
2.1.6. PDO 
Unlike the above, the biodegradable aliphatic polyester polydioxanone (PDO) has received 
limited interest until recently. It was first used in 1981 as a monofilament suture [33] but only now 
has been applied to other uses, including stents, rings for pediatric mitral and tricuspid heart valve 
repair and as plates for orbital floor reconstruction [34]. PDO presents a good safety profile with low 
toxicity in vivo and is capable of completely degrading between 6 and 12 months, depending on its 
degree of crystallinity, which also affects the polymer absorption rate. Compared to PGA, PLA and 
their derivatives, PDO displays a lower tensile modulus with limited mechanical performance. 
However, is still suitable for a wide range of tissue engineering applications like cartilage, ligament 
and vascular tissue engineering [35,36]. 
2.2. Natural-Origin Polymers 
Regarding natural polymers, the majority degrade very quickly via enzymatic degradation. The 
rate of degradation depends on the implantation site, accessibility to and concentration of enzymes 
and possible chemical alterations made to their structure. They are also susceptible to cell-triggered 
proteolytic degradation [16]. Natural polymers have been used for many years in tissue engineering. 
They are classified as polysaccharides, polymeric carbohydrate molecules formed of glycosidic-
bound monosaccharide units such as alginate, hyaluronic acid, cellulose and chitosan, and as 
polypeptides, peptide bound amino acid chains that include collagen and gelatin, for instance [37–
39]. 
2.2.1. Alginate 
Alginate is a polyanion, typically obtained from brown seaweed, that possesses solubility in 
water, great biocompatibility and low toxicity and is biodegradable and of relatively low cost. Most 
alginates can be processed in the form of hydrogels, porous scaffolds, microparticles and 
nanoparticles [40]. Alginates are readily degraded by naturally occurring enzymes, i.e., lysases. Their 
physical and mechanical properties are dependent on the length, molecular weight and proportion 
of the guluronate block within the polymeric chain [41,42]. Alginates can be prepared by various 
cross-linking methods in a similar way to the extracellular matrix of living tissue, making them 
desirable for applications in wound healing, drug delivery, and cell transplantation [40,43]. 
2.2.2. Hyaluronic Acid 
Hyaluronic acid is a glycosaminoglycan made up of repeating disaccharide units of D-
glucuronic acid and β-1,3-N-acetyl-D-glucosamine. It is commonly found in conjunctive tissues of 
any vertebrate and can be rapidly biodegraded by the human body [44]. Hyaluronic acid is also a 
polyanion that can self-associate and bind to water molecules, giving it a stiff, viscous quality similar 
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to gelatin [45]. Because of its unique rheological properties and complete biocompatibility, hyaluronic 
acid has been used quite extensively in biomedical applications, playing a significant role as an 
antifouling agent protecting blood-contacting devices, in wound healing, biomolecule delivery and 
tissue regeneration [46,47]. 
2.2.3. Cellulose 
Cellulose is an abundant polysaccharide based on glucose and is present in plants, bacteria, 
fungi, algae and animals. Cellulose can also be biosynthesized by bacteria in the form of bacterial 
cellulose. It exhibits a unique nanostructure, remarkable physical-chemical properties and 
biocompatibility and is resistant to hydrolysis, strong alkali and oxidizing agents [48,49]. Cellulose 
on its own cannot be electrospun. However, each repeated unit of cellulose possesses three hydroxyl 
groups on its structure, which can be replaced by other chemical groups, such as methyl, acetyl, and 
carboxymethyl, and thus, several derivative compounds can be synthesized [50]. The acetate ester of 
cellulose, also known as cellulose acetate, is the most commonly used. Due to its unique properties 
such as high tensile and impact strength, good antistatic properties, good transparency, excellent 
scratch resistance, high moisture absorption, and permeability, cellulose esters have found numerous 
applications in biomedicine [13,26,51,52]. 
2.2.4. Chitosan 
Chitosan is the most widely used natural polymer in drug delivery due to its ability to blend 
with a variety of synthetic polymers and facile surface modification. Derived from partially 
deacetylated chitin found in the shell of crustacean, cuticles of insects and cell walls of fungi 
microorganisms, it is composed of D-glucosamine and N-acetylglucosamine repeat units, forming 
the only pseudonatural cationic polymer. By varying the degree of deacetylation, viscosity and 
molecular weight, a series of chitosan polymers may be generated [53,54]. The degree of deacetylation 
of typical commercial chitosan is usually between 70% and 95%, and the molecular weight can range 
from 10 to 1000 kDa. These three factors (degree of deacetylation, viscosity and molecular weight) 
are also determinant to the polymers’ physical and chemical properties. Regardless, all chitosan 
polymers are known for their biocompatibility, biodegradability, antimicrobial activity, wound 
healing abilities and antitumor effect [55]. Chitosan solubility in aqueous solutions makes it 
processing into gels, films or fibers possible [56–58]. 
2.2.5. Collagen 
Collagen is the most abundant mammalian protein, accounting for around 30% of all body 
proteins, and is a major component of ligaments, tendons, skin and bone [59,60]. In its native 
environment, collagen interacts with cells in connective tissues and transduces essential signals for 
the regulation of cell anchorage, migration, proliferation, differentiation and survival. It is composed 
of polypeptide strands bearing triamino acid blocks of glycine-X-Y, where X and Y can be any of a 
number of amino acids, that organize themselves into left-handed triple helix microfibrils [61]. 
Collagen is a good surface-active agent and is capable of penetrating within lipid-free interfaces. It is 
desirable in many biomedical applications because of its biodegradability, high mechanical strength, 
weak antigenicity and superior biocompatibility compared with other natural polymers, i.e., gelatin 
[60,62–64]. Electrospinning of soluble collagen is a suitable method to prepare scaffolds with high 
porosity and surface area for tissue engineering [58]. 
2.2.6. Gelatin 
Gelatin is a natural polymer derived from the controlled structural and chemical degradation of 
collagen and contains a large number of glycine, proline and 4-hydroxyproline residues. Gelatin 
comprises many functional groups and cell-binding sites in its structure, increasing its cell-binding 
ability and making it desirable for tissue engineering applications. It is also commonly used to 
produce biocompatible and biodegradable biomolecule delivery systems and wound dressings. In 
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fact, targeted tissues include bone, cartilage and skin, but others such as adipose tissue have also 
applied gelatin as a carrier for the delivery of active biomolecules using the process of encapsulation 
to improve temporary cell functions [58,65,66]. 
2.3. Bio-Synthetic Hybrid Polymers 
As seen, the most relevant properties of natural polymers are their bioactivity (biological 
recognition), biocompatibility, antigenicity and non-toxicity (which reduces undesirable host 
responses), tunable degradation kinetics and, in many cases, presence of cell-recognition sites. 
However, these materials may also display limitations that include weak mechanical strength, rapid 
or unregulated degradation rate and inconsistency in composition (lack of reproducibility of 
properties between batches) due to their natural source. In turn, synthetic polymers are easily 
processed at a large scale, are relatively low cost and display controlled properties, including 
molecular weight and functionality. Despite these important advantages, one main drawback haunts 
synthetic polymers and restricts their application in biomedicine, namely the inability to be 
recognized by cells and consequently induce their adhesion and proliferation [67]. 
The rationale behind preparing hybrid polymers instead of using single-component polymers is 
to combine the positive functionalities of both natural and synthetic to generate a construct that 
exceeds the individual properties of each individual polymer composing the hybrid [68]. Synthetic 
polymers with good mechanical properties but lacking motifs for cell recognition, attachment or 
proliferation can be combined with small amounts of natural-origin polymers to enhance these 
properties and, this way, generate a material with easier processability. Even though these 
modifications may lead to better-performing materials for applications in tissue engineering or drug 
delivery systems, synthesizing hybrid materials can be very challenging, especially when different 
fabrication techniques must be employed. Therefore, a balance between the complexity of the 
production and fabrication processes and the benefits presented by the hybrid materials must be 
maintained [69,70]. 
Tissue-engineered scaffolds are being developed as treatment options for malfunctioning tissues 
throughout the body. Therefore, it is essential for the scaffold to closely mimic the native tissue with 
regards to both mechanical and biological functionalities. For instance, the use of synthetic polymers 
modified with collagen increases the scaffold mechanical strength. Moreover, loading bioactive 
molecules, such as growth factors, into collagen-based scaffolds and gels enhances their regeneration 
and restorative effects. The main challenge in drug delivery systems made of hybrid polymers 
remains the liberation of selected biomolecules at specific targets. The dominant route for drug 
administration is through oral routes or intravenous injections, but these methods have limited access 
over the drug release rate in the body as they show a tendency for immediate burst release. To 
overcome this issue, hybrid polymers engineered with chemically modified chitosan or cellulose are 
finding applications in multiple areas, including cell encapsulation, wound dressings and implants, 
with effective outcomes [13,58,71,72]. 
3. Biotextiles Production: Fiber Technologies 
The history of fiber production by humankind can be traced back to prehistoric times. Fragments 
of cotton articles dating back to 5000 BC have been excavated, and silkworm cultivation began in 
2700 BC to produce silk fibers and textiles. Around 1300, the spindle was invented to fabricate fibers 
from wool and cotton used in fabrics and clothes, and this practice slowly evolved into the textile 
industry in the 1880s. About 50 years later, production of synthetic fibers initiated and with that the 
development of chemistry and polymer sciences [73]. 
Nowadays, several fabrication methods can be applied to convert polymers into fibers. The 
resulting fibers can either be continuous monofilament yarns or multifilament yarns or, alternatively, 
they can be divided into short-length staple fibers and blended with natural fibers such as cotton or 
wool or used by itself in the manufacture of scaffolds. To this aim, 3D printing and fiber spinning 
technologies can be regarded as the most prominent techniques in this field [74,75]. 
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3.1. Fiber Extrusion Spinning 
Great progress in spinning polymer fibers for biotextiles has been achieved over the past few 
decades [76]. Spinning is a specialized form of extrusion that uses a spinneret to form mono or 
multiple continuous filaments and is considered an interdisciplinary technique that applies the 
principles of engineering and material science. The three principal spinning methods conventionally 
used to manufacture fibers are wet-spinning, dry-spinning and melt-spinning [77,78]. 
The first step to producing fibers by spinning techniques is to convert the polymer into a 
processable and spinnable state. Thermoplastic polymers can be converted into a fluid state and melt-
spun [79]. Other polymers may be dissolved in a solvent or chemically treated to form soluble or 
thermoplastic derivatives and subsequently spun via dry-spinning, wet-spinning or electrospinning, 
a most recent approach to spinning at the nanoscale. The main traditional spinning approaches used 
in the fabrication of biotextiles are introduced in the following sections. 
3.1.1. Melt-Spinning 
Melt-spinning is the most economical spinning process as it does not require solvents to process 
the polymers. For that reason, it is the preferred method for manufacturing polymeric fibers, being 
extensively used in the textile industry. However, this technique presents limitations to its use in the 
production of biostructures, including decomposition at temperatures below the melting point, poor 
control over the exact temperature of the polymer melt during spinning, thermo-mechanical history 
of the melt and final fiber structure/morphology [80]. 
In the melt-spinning process, dried polymer granules or chips are melted inside the extruder in 
order to obtain the spinning dope. This viscous melt is then extruded through a spinneret, and the 
obtained filament is quenched and solidified by cooling in a fast fiber solidifying process [81]. Despite 
its limitations, melt-spinning of biopolymers from different sources has been extensively explored in 
bio-applications (Table 2) [82]. The use of bio-based reinforcements is reported as an alternative to 
solve the problems associated with the synthesis of biotextiles via melt-spinning [83]. 
Table 2. Some of the representative spinning systems studied for biomedical applications. 
Polymeric 
Matrix Processing Method Bio-Application Reference 
PLA/CNW  Melt-spinning - [83] 
PHBV/PLA Melt-spinning Textile implants [82] 
PLGA Dry/wet and Wet-
spinning 
Scaffolds production [84] 
CS Dry-spinning Tissue regeneration [85] 
PCL Wet-spinning Regeneration of smooth muscle 
cells 
[86] 
GN Wet-spinning Tissue regeneration [87] 
GN/SA Wet-spinning Enzyme immobilization [88] 
PCL Wet-spinning 
Regeneration of smooth muscle 
cells [86] 
Collagen Wet-spinning - [89] 
CA Wet-spinning Drug delivery systems [90] 
PCL Electrospinning Tendon graft [91] 
GN Electrospinning Wound healing [92] 
CS/SF Electrospinning Wound healing [93] 
Abbreviations—CNW: nanocrystalline cellulose; PHBV: poly[(3-hydroxybu-tyrate)-co-(3-
hydroxyvalerate)]; CS: chitosan; GN: gelatin; SA: sodium alginate; CA: cellulose acetate; SF: silk 
fibroin. 
3.1.2. Dry-Spinning 
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Dry-spinning is one of the oldest spinning methods in use. Contrary to melt-spinning, in dry 
spinning, the polymer is dissolved in an appropriate solvent. The polymer solution is then extruded 
through a spinneret, subsequently passing through a heating column, where the solvent evaporates, 
leaving behind dry fibers (in this case, highly volatile solvents are required). In the heating column, 
steam of hot air or inert gas is used to solidify the fibers and remove the solvent. This technique is 
suitable for polymers vulnerable to thermal degradation and cannot form viscous melts, and for 
when specific surface characteristics are required from fibers. Several polymer fibers have been 
traditionally processed using dry-spinning techniques, including acetate and triacetate, some 
modifications of acrylics and modacrylics, aramid fibers and spandex fibers [77,78]. Apart from the 
recovery process, the mass transfer mechanisms involved in the solvent evaporation and filament 
formation make dry-spinning more complex and expensive than melt-spinning [79]. 
3.1.3. Wet-Spinning 
The first fiber to be spun by wet-spinning was rayon, with an alcoholic solution of cellulose 
nitrate extruded from a nozzle dipped in cold water. Since then, many natural and synthetic polymers 
have been produced via wet-spinning [94]. Like dry-spinning, in the wet-spinning technique, the 
polymer needs to be dissolved in a suitable solvent in order to be spun. However, here, the solvent 
does not need to be volatile [95]. 
Wet-spinning is based on the principle of precipitation, in which a phase inversion occurs during 
the extrusion of the polymeric solution through a spinneret directly into a coagulation bath composed 
of a non-solvent liquid [75]. Natural-origin polymers such as gelatin, alginate, collagen, cellulose and 
many of their composites have been processed in the form of fibers using wet-spinning for a variety 
of tissue engineering uses (Table 2). This technique allows the production of fibers with relatively 
large diameters (in the nano-to-micrometer ranges) and the construction of architectures with high 
porosity and interconnected open pore structure, which are desirable for cell penetration, adhesion 
and proliferation [96]. 
3.1.4. Electrospinning 
Electrospinning is a unique spinning approach that resorts to electrostatic forces to produce fine 
fibers (from nanometer to micrometer) from polymer solutions or melts with a larger surface area 
than those obtained from conventional spinning processes [97]. 
Electrospinning has attracted much attention in biomedical research because of the inherent 
properties of the resultant nanofibers, such as large surface areas, high porosity and a continuous 
three-dimensional web structure [6,39,98]. The process involves the ejection of a polymer solution 
through a needle, termed the spinneret, that under an electric field is attracted towards a collector 
plate. A high potential difference is applied between the two, resulting in the conversion of the initial 
solution into nanofibers [39,99,100]. 
Nanofibrous scaffolds have shown great potential and usefulness for assisting the regeneration 
and reconstruction of different types of human tissues and organs, ranging from bone, skin and blood 
vessels to organs like liver and kidneys [101]. Early research revealed that electrospun nanofibrous 
scaffolds of biodegradable polymers could closely mimic the hierarchical architecture of native 
extracellular matrix and facilitate good attachment and proliferation of cells. Later, the potential of 
highly biocompatible electrospun scaffolds for engineering many types of human body tissues with 
relatively simple structures was shown and is now frequently realized [102]. 
3.2. 3D-Printing 
Printing methods have raised great attention in recent years as fast and inexpensive ways of 
manufacturing several materials. The 3D printing technique, which is an additive manufacturing 
technique, was initially conceived in the 1980s. Since then, this technique has impacted many fields, 
entering just recently the biomedical area [103]. 3D printing of complex biomedical devices designed 
using patient data is an expanding field of research, and applications can range from the 
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reconstruction of complex organs with intricate 3D microarchitecture (e.g., liver, lymphoid organs) 
to scaffolds for stem cell differentiation [104]. 
In general, 3D printing includes different printing technologies to generate 3D structures by 
adding layers upon layers of materials, such as ceramics, metals or polymers (synthetic or natural) 
[105]. The standard for 3D printing technologies (ASTM F2792) is applied to several rapid 
prototyping processes such as vat photopolymerization, material jetting, material extrusion, powder 
bed fusion, binder jetting, sheet lamination and directed energy deposition. The vat 
photopolymerization 3D printing method has a container with a photopolymer resin hardened by 
means of a power source (e.g., ultraviolet light). Here, the most common technique employed is the 
stereolithography (SL) [106,107]. In bioprinting, SL can generate multiple cycles to form a 3D 
structure by photopolymerization/cross-linking of polymers [103]. The main disadvantage of using 
such technology for biomedical purposes is the need for intense ultraviolet radiation during cross-
linking. Other limitations are the lengthy post-processing time requirement and the lack of diversity 
of biomaterials that can be applied as “biomaterial inks” (bioinks) [108]. Gelatin- and alginate-derived 
bioinks, for instance, suffer from poor shape fidelity and poor printing resolution and form very soft 
gels at physiologic temperatures [109]. Strategies to improve these limitations have been employed, 
such as introducing new functional groups via crosslinking and forming composites of natural and 
synthetic bioinks. These efforts have been rewarded with an improved printing fidelity, resolution 
and mechanical integrity that does not interfere with the inherent biocompatibility of natural bioinks 
[110]. 
Another potential application of 3D bioprinting is in tissue replacement and restoration using 
seeded stem cells. One of the major advantages of bioprinting compared to conventional tissue 
engineering strategies is the ability to influence stem cell differentiation at multiple stages. The choice 
of stem cell source, bioprinting method, scaffold architecture, additives used and mechanical forces 
applied can influence stem cell differentiation towards a specific target tissue [103]. 
4. Tissue Engineering 
In tissue engineering, principles from biology, chemistry and engineering sciences are combined 
towards the common goal of regeneration. Engineering living systems for regeneration purposes 
requires appropriate cell sources, optimal culture conditions, and biodegradable implantable devices. 
In the first two cases, consensus has been reached by recommending the use of specialized cells or 
mesenchymal stem cells capable of differentiation, and bioreactors to provide optimal and controlled 
culture conditions. Regarding the biodegradable implants, the construct is expected to guide cell 
growth and tissue formation with time in three dimensions. As described in Section 2, there are many 
polymers capable of such a task [6,39,111]. Fibers and biotextiles have been successfully used in close 
contact with complex biological environments for a variety of applications, both by itself or loaded 
with specific biomolecules, due to their similarity with the tubular and fibrous architecture of many 
tissues, including muscle, tendon, ligament, bone and teeth [112]. In the following sections, examples 
of soft and hard tissue applications of fiber-based constructs in tissue engineering are provided. 
4.1. Stents 
Stents are small, expandable reticulated tubes with two main functions, the treatment of 
dissection and prevention of restenosis. Biodegradable stents are expected to provide a temporary 
opening of a narrowed arterial vessel until remodeling occurs and to disappear progressively 
thereafter. Indeed, an ideal biodegradable stent should be able to compromise its degradation rate 
and mechanical integrity during implantation and after it, during the 6 to 12 months expected for the 
remodeling process to be completed [113]. 
The first biodegradable stent was developed in 1988 by Stack et al. using PLLA and was almost 
completely degraded after 9 months. Clinical research on animal models revealed minimal presence 
of thrombosis, moderate neointimal growth and limited inflammatory response [114]. Later, it was 
demonstrated that low-molecular-mass PLLA was associated with intense inflammation, while the 
inverse was also true [115]. This was tested on different animal models: in dogs, minimal tissue 
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growth was observed [116], while in pigs, marked cell proliferation occurred [117]. Yamawaki et al. 
were the first to incorporate an anti-proliferative agent on high-molecular-weight PLLA stents and 
to verify that neointimal formation was significantly reduced in the presence of the loaded tube. 
Nguyen et al. evaluated the hemocompatibility profile of PLLA stent fibers loaded with anti-
inflammatory and anti-proliferative drugs, curcumin and paclitaxel by employing a closed-loop 
circulation system filled with human blood. Data revealed curcumin as more effective than paclitaxel, 
the activity of which may have been inhibited during melt extrusion, in reducing leukocyte and 
platelet adhesion and activation to the stent fibers [118]. More recently, Quin et al. used PDO 
monofilaments coated with small intestine submucosa to braid mesh stents. After 24 weeks 
implantation in dog animal models, the stents were completely degraded [119]. It has been shown 
that PDO filaments can lose up to 60% of their initial strength after 6 weeks of degradation in 
phosphate buffer saline solution, while preserving the stent well radial strength [120]. This was 
corroborated by Wang et al., whose PDO monofilaments braided in the form of a stent were capable 
of retaining half of their original strength after 6 weeks of degradation but lost it completely after 10 
weeks. In the end, the stents demonstrated good compression performance up to 12 weeks and 
therefore could become a good alternative for short-term applications [121]. 
Genistein-conjugated PLLA has been synthesized by direct coupling with a unique influence on 
coagulation, plasma protein adsorption and subsequent platelet adhesion and activation. Genistein 
is a potential flavonoid endowed with anti-thrombotic and anti-proliferative properties, capable of 
inducing human platelet aggregation in a dose-dependent manner via nitric acid-dependent signal-
transducing pathways. This fibrous system was designed for potential applications in coronary stents 
[122]. Drug loaded PLLA has also been conjugated with the two ends of the matrix metalloproteinase-
9 (MMP-9) for a selective drug release, beneficial for stent endothelialization, thereby decreasing the 
risk of restenosis and thrombosis [123]. Tyrosine kinase inhibitor (ST638) was encapsulated onto 
prototype Igaki–Tamai stents and implanted in porcine coronary arteries. Data revealed the 
progressive, gradual release of the ST638 decreasing neointimal hyperplasia [117]. More recently, 
using a conventional emulsion solvent evaporation method, sirolimus-encapsulated PDLLA 
nanoparticles were produced and coated onto stents for a sustained biomolecule release. Cell culture 
studies demonstrated the ability of the fashioned stents to inhibit smooth muscle cell proliferation 
while accelerating endothelial cells, therefore unveiling the potential of these stents to decrease both 
the occurrence of in-stent restenosis and acute thrombosis [124]. 
4.2. Skin 
Skin is the largest organ in the body, formed mainly of two layers, the epidermis and the dermis, 
and primarily serves as a protective barrier against the environment. Skin wounds normally heal in 
a predictable amount of time by forming an epithelialized scar tissue. However, whenever burns, 
trauma, irreversible damaged skin or chronic wounds occur, the need for substitutes or more efficient 
protective barriers is raised (Figure 2) [39]. Engineered skin tissue and high-performance wound 
dressings would be an excellent solution. Although allografts and autografts have been the most 
obvious choice in the past, lately, temporary three-dimensional tissue engineering constructs 
mimicking the skin architecture and loaded with fibroblasts, keratinocytes and endothelial cells have 
gained more attention [10,125]. 
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Figure 2. Depiction of acute and chronic wound scenarios with dysregulated matrix 
metalloproteinases (MMPs) and infiltration of bacteria (used with permission from [126]). 
Biodegradable fiber-based structures have been proposed for the healing of dermal and 
epidermal injuries. In fact, PLGA fibrous dressings have been already successfully used in clinical 
patients diagnosed with diabetic foot ulcers (i.e., Dermagraft and Dermagraft-TC) [127]. Thin 
biodegradable hybrid meshes of PLGA and collagen have also been produced for culture of human 
skin fibroblasts. Results indicated the web-like collagen formations distributed along the PLGA 
knitted fibers increased the fibroblasts seeding and distribution and facilitated rapid formation of 
dermal tissue with uniform thickness [128]. Recently, Norouzi et al. produced nanofibers of PLGA 
and gelatin via electrospinning and demonstrated desirable bioactivity and hemostasis of the fibrous 
scaffolds with controlled release of the protein [129]. Electrospun PLGA nanofibers have also been 
encapsulated with epidermal growth factors (EGF), resulting in desirable biocompatible and 
bioactive scaffolds with EGF controlled release [130]. 
Collagen-based scaffolds have been the most popular for skin regeneration, both alone and in 
combination with other polymeric matrices or molecules (growth factors, proteins, etc.). For instance, 
dermal substitutes composed of type I collagen and elastin hydrolysate, applied in combination with 
split-skin mesh grafts, contributed to the healing of full-thickness wounds [131] and improved 
dermal regeneration [132]. It has also been shown that preparations of collagen type I and PCL result 
in optimal degradation kinetics and mechanical performance while supporting dermal fibroblasts 
attachment and proliferation. Developing a porous structure expedited the healing process, assisted 
in re-epithelialization and follicle regeneration, and promoted the formation of dermal tissue with a 
matrix architecture resembling normal, unwounded skin [133]. Additionally, they revealed that these 
microporous electrospun constructs pre-seeded with fibroblasts promoted greater wound healing 
than acellular scaffolds [134]. 
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Nada et al. combined cellulose acetate with capsaicin, a pain-relieving drug, and sodium 
diclofenac, a nonsteroidal anti-inflammatory drug that reduces the action of substances responsible 
for causing pain and discomfort, in an electrospun mat and generated a controlled released system 
that accelerated patient relief [135]. To confer biocidal properties to cellulose acetate-based 
nanofibers, Jiang et al. modified their surface with 4,4’-diphenylmethane diisocyanate (MDI), with a 
complete death of bacteria colonizing the wound after a 30 min contact [136]. The improved 
synergistic effect of the oregano essential oil with cellulose acetate-based nanofibers against 
Staphylococcus aureus, Escherichia coli and the yeast Candida albicans infecting wounds has also been 
demonstrated and explained on the basis of the potent antimicrobial character of oregano oil’s 
molecular components carvacrol and thymol [137]. Cinnamon, lemongrass and peppermint essential 
oils loaded onto cellulose acetate electrospun mats have also shown similar outcomes. However, even 
though fibroblasts and human keratinocytes could attach and spread on the fibers’ surface, cell 
viability seemed to decrease with exposure time [138]. The anti-proliferative effect of essential oils 
against eukaryotic cells remains a challenge in tissue-engineering applications and biomolecule 
delivery systems. 
As seen, synthetic biodegradable polymers such as PLA, PGA, PLGA and PCL have all been 
used as matrices for skin regeneration, both individually and in combination with other natural-
origin polymers. They have been processed in the form of nanofiber matrices with large surface area, 
high wound exudates absorbency capacity, and high oxygen permeability. In addition, the small pore 
size has been regarded as an extra barrier to prevent bacterial penetration [39]. 
4.3. Nervous System 
The nervous system is a complex organization of neurons or glial cells that regulate and 
coordinate body activities. Degeneration of these cells results in changes in the extracellular matrix 
of the neural tissue that trigger a variety of clinical disorders. Since neurons cannot regenerate by 
themselves, restoration of their functions by means of biological and synthetic tools, processed in the 
form of fibrous scaffolds or biomolecule delivery systems, is a priority [139,140]. 
Cells live in a complex mixture of pores, ridges and fibers in the extracellular matrix. Mimicking 
those conditions via porous, interconnected nanostructured constructs with large surface areas is 
recommended for the cells’ successful in-growth [39,141]. In fact, nerve stem cell differentiation and 
neurite outgrowth have been successfully supported by PLLA nanostructured porous scaffolds, 
demonstrating their potential cell carrier in nerve tissue engineering. Here, scaffolds are produced 
using advanced techniques in the form of complex guidance channels, which precisely mimic the 
natural repairing process in the human body [142]. The efficacy of PLLA nano- and microfibrous 
scaffolds produced via electrospinning was also examined under optimal conditions of fiber 
alignment and tailored diameters by culturing neural stem cells. Results showed the neural stem cells 
elongation and neurite outgrowth to be parallel to the direction of the PLLA fibers. The rate of 
differentiation was also higher on nanofibers than on microfibers [143]. Prabhakaran et al. developed 
PCL nanofibrous constructs and modified their surface by a simple plasma treatment. The goal was 
to improve Schwann cell adhesion, proliferation and interactions along the nanofibers for nerve tissue 
formation. After 8 days of culture, cells attached and proliferated on the surface-modified scaffold, 
expressing bipolar elongations and retaining their normal morphology. In addition, data showed this 
treatment to be more cost-effective than the production of PCL/collagen scaffolds, adding evidence 
to their potential to serve in peripheral nerve regeneration [144]. Reports on PCL/gelatin nanofibrous 
scaffolds have also shown to enhance nerve differentiation and proliferation and to support neurite 
outgrowth. Once again, the nerve cell elongation followed the alignment of the nanofibers and 
established this biocomposite suitability for nerve regeneration [145]. More recently, both PCL and 
gelatin were used for neural differentiation of human-induced pluripotent stem cells in the form of 
bi-electrospun nanofibers. The nanofibers supported the stem cells’ differentiation into neural cells 
and were able to improve the entire process [146]. The selection of PLLA, PLGA and PCL as base 
polymers to produce fibrous scaffolds for nerve tissue engineering is based on their mechanical 
stability, exceptional biocompatibility and, most importantly, their slow biodegradability. This 
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allows for cells to adhere and differentiate into neural cells with no danger of losing their supporting 
matrix before the entire local neural network is restored. 
Core-shell PLGA nanofibrous nerve guidance conduits loaded with nerve growth factors were 
fabricated via co-axial electrospinning and used to construct nerve guidance conduits for a 13 mm 
rat sciatic nerve defect. After 12 weeks of implantation, the aligned core-shell nanofibers promoted a 
superior functional recovery, with more nerve fibers being regenerated and displaying a more mature 
morphology than in the control group (bare PLGA) [147]. Co-axial nanofibers with poly(L-lactide-co-
ɛ-caprolactone) (PLLACL, derived from the merge of PLLA and PCL) at the shell and bovine serum 
albumin combined with nerve growth factors at the core were produced with a sustained release that 
promoted the differentiation of rat pheochromocytoma cells (PC12). In co-axial systems, the 
biomolecules' release profile can be finely tailored by modulating the morphology, porosity and 
composition of the nanofibers. Besides, diameters at nanoscale provide short diffusion passage length 
and a high surface area very effective for controlled mass transfer [148]. Nerve growth factors have 
also been loaded onto PLLACL/silk fibroin solutions to produce co-axial fibers with a sustained 
release that lasted over 60 days. Here too, nerve guidance conduits were fabricated by reeling the 
aligned PLLACL/silk fibroin nanofibers and implanting these structures onto sciatic nerve defects in 
rats for 12 weeks. In the end, data demonstrate the ability of these structures to promote peripheral 
nerve regeneration by the local, controlled release of nerve growth factors [149]. PLLACL/silk 
solutions have been modified with Vitamin B5 to produce aligned nanofiber meshes; 80% of the 
Vitamin B5 content was released within 24 h, demonstrating this drug delivery system strategy’s 
potential to increase cell survival and proliferation and, ultimately, for applications in nerve repair 
or regeneration [150]. In another strategy, PCL and chitosan were blended to form nanofibrous 
scaffolds, via electrospinning, with excellent mechanical and surface properties. The surface of the 
scaffolds was functionalized with laminin via carbodiimide-based cross-linking. Data reported the 
successful growth and proliferation of Schwann cells within the laminin-loaded polymeric matrix 
and its versatility for in vivo cell delivery for nerve tissue engineering [151]. The important role 
played by PCL and PLLACL in nervous system research has been extensively confirmed. In fact, its 
use as a suitable platform for neuronal cell growth and proliferation is here extensively demonstrated. 
However, on its own, these polymers are barely effective, requiring growth factors and other 
biomolecules to be loaded onto their structure to stimulate the development and growth of the neural 
cells. 
4.4. Vascular Grafts 
Cardiovascular diseases are the number one cause of death globally. They are commonly 
associated with the narrowing blockage of blood vessels leading to reduced blood flow and 
inadequate nutrient supply. Synthetic vascular grafts have become a recurrent alternative to replace 
or bypass a damaged or occluded vessel [152]. In the first attempts to develop vascular grafts, non-
biodegradable polymeric fiber structures made of Dacron and Teflon were employed [153]. Only 
later, arterial regeneration was demonstrated over woven PGA biodegradable constructs in rabbit 
models [154] or on microporous, compliant, non-thrombogenic L-polylactide-polyurethane (PLLA-
PU) [155]. From then on, many different studies were conducted to improve the properties of 
biodegradable scaffolds and develop blood vessel substitutes. The goal was to engineer 
biodegradable grafts to serve only as skeleton constructs to induce and support tissue overgrowing 
and ingrowing. For instance, Sell et al. designed a PDO and elastin vascular graft via electrospinning, 
conducive to tissue regeneration, with mechanical properties that closely matched the native arterial 
tissue. They determined that a 50/50 ratio between the two biodegradable polymers was preferred to 
mimic the compliance of the native femoral artery and established elastin-containing grafts as 
bioactive, promoting cell migration [156]. Jeong et al. created a novel tubular scaffold from marine 
collagen and PLGA fibers that improved the mechanical strength of the collagen-based synthetic 
grafts in both dry and wet states. The proliferation and phenotype expression of smooth muscle cells 
and endothelial cells was followed on static and dynamic conditions. It was observed that under a 
pulsatile perfusion system, both cell proliferation and alignment along the PLGA fibers was 
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improved and that cells were capable of retaining their differentiated cell phenotype [157]. A bi-layer 
of type I collagen was also tested in vivo as a small diameter vascular graft to promote the complete 
regeneration of rats' inferior vena cava. After 12 weeks of implantation, a thin continuous layer of 
endothelial cells and smooth muscle cells was lined with the vascular lumen and tunic media, 
proving that the engineered vascular substitute not only possessed sufficient tensile strength and 
good biocompatibility but also advanced vascular regeneration [158]. More recently, PCL micro- and 
nanofibrous vascular grafts were engineered via electrospinning, and their long-term performance 
was investigated in vivo. PCL grafts were implanted in rat models at the abdominal aorta region up 
to 18 months, and their compliance, tissue regeneration and degradation rate were followed. Results 
showed excellent structural integrity, with no aneurysmal dilation, and perfect patency with no 
thrombosis and limited intimal hyperplasia. Cell migration and neovascularization increased quickly 
throughout time. Degradation data was inclusive [159]. In another in vivo study, PCL scaffolds were 
prepared with thicker fibers and larger pore structure and implanted in the abdominal aorta of rat 
models for 100 days. The macroporous vascular grafts enhanced cell infiltration and extracellular 
matrix secretion. At the end of the implantation period, endothelium coverage was complete, and the 
regenerated smooth muscle layer was correctly organized. More importantly, the regenerated arteries 
demonstrated a contractile response to adrenaline and acetylcholine-induced relaxation. These 
thicker-fiber electrospun scaffolds were also seen to attract and mediate macrophage polarization 
into the immunomodulatory and tissue remodeling phenotype [160]. To balance the degradation rate 
of PCL, fibrous grafts have also been prepared from blends of PCL and PDO. Pan et al. produced 
small-diameter hybrid grafts by co-spinning and followed their regeneration abilities in rat 
abdominal aorta replacement models up to 3 months of implantation. Degradation of PDO provided 
extra space within the graft, which facilitated vascular smooth muscle regeneration within PCL/PDO 
grafts. Coverage by endothelial cells was superior on PCL/PDO than on PCL grafts due to the increase 
in the construct’s hydrophilic nature. Heparin-loaded PCL nanofibers have also been prepared via 
co-axial electrospinning. An initial burst release of heparin (50%) was observed, followed by a more 
gradual release of up to 72% of its content within the following 2 to 14 days. Evaluation with a canine 
artery model revealed the potentialities of this system to greatly enhance the patency rate of small-
diameter grafts [161]. Heparin has been combined with vascular endothelial growth factors (VEGFs) 
and loaded onto PLLACL (or PLCL), electrospun nanofibers for anticoagulation and rapid 
endothelization purposes. After adding Span-8 to the mixture, the synergistic action of heparin and 
the VEGFs was enhanced with a sustained release for 29 days that improved the scaffold 
anticoagulation capacity and accelerated endothelial progenitor cell growth (Figure 3) [162]. 
Salvianolic acid B (SAB), a traditional Chinese medicinal plant known to promote proliferation and 
migration of endothelial cells was combined with heparin to form a core solution in a PCL/collagen 
shell. A sustained release of 56% of SAB and 68% of heparin within the first 30 days was observed. In 
a rat subcutaneous embedding model, the biocompatibility of the engineered scaffold was confirmed, 
uncovering this strategy as promising for preventing acute thrombosis and for promoting rapid 
endothelialization [163]. 
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Figure 3. (a) Endothelial progenitor cell growth from 1 to 7 days (PLCL-W, control without 
biomolecules; 15Hep, 15 wt% heparin; 10, 20 and 30 vascular endothelial growth factors (VEGF) 
represent 10, 20 and 30 μg/mL of VEGF) and visual detection of the cells via (b) immunofluorescent 
microscopy (scale 200 μm) and (c) scanning electron microscopy (SEM, scale 100 μm) (adapted with 
permission from [162]). 
4.5. Bone  
Bone is a mineralized connective tissue with functions of support and protection in the human 
body that, despite its inert appearance, is highly dynamic, being continuously resorbed by osteoclasts 
and neoformed by osteoblasts [164]. It is a very complex system with a large amount of extracellular 
matrix and a limited cell population [127]. A variety of materials have been used in the production of 
such biodegradable fibrous constructs for replacement and repair of damaged or traumatized bone 
tissues. Typically, engineering bone requires an artificial extracellular matrix or fibrous and highly 
porous scaffold, osteoblasts or cells that can differentiate into osteoblasts, and regulating factors or 
bioactive molecules to instigate cell recruitment, differentiation and mineralization to form new bone 
tissue [165,166]. 
Lisignoli et al. developed a non-woven hyaluronic-acid-based polymer scaffold combined with 
bone marrow stromal cells and fibroblast growth factors and followed the osteogenesis of large 
segmental radius defects in rat models, up to 200 days of implantation. It was seen that bone 
mineralization was significantly induced by the presence of the growth factors, detected by the 
improved expression of important bone markers (i.e., alkaline phosphatase, bone sialoprotein, 
collagen type I, etc.). Further, new bone growth and lamellar bone percentage were highly correlated 
[167]. Mineralization and type I collagen production were also improved using microporous, non-
woven, electrospun PCL scaffolds cultured with mesenchymal stem cells derived from the bone 
marrow of neonatal rats. After 4 weeks of culture, cells were seen to penetrate the scaffolds and to 
give rise to an abundant extracellular matrix [168]. Using an equal combination of scaffold and cells, 
Shin et al. supplemented these constructs with osteogenic factors using a rotating bioreactor and then 
implanted them in the omenta of rats for 4 weeks to assess new bone formation in vivo. It was 
observed that the constructs maintained their size, shape and bone-like appearance at the end of the 
4 weeks and that cells and extracellular matrix covered the entire fibrous construct. Moreover, 
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mineralization and type I collagen were also detected [169]. PCL has also been blended with PLA to 
produce nanofibrous, highly porous scaffolds with interconnected open porous structure with 
improved mechanical stiffness and bioactivity. Results showed that this combination not only 
enhanced cell viability of human mesenchymal stem cells but also promoted osteogenic 
differentiation. In addition, PCL/PLA scaffolds were seen to facilitate new bone formation in a 
critical-sized cranial bone defect mouse model [170]. Ye et al. engineered a scaffold of nano-
hydroxyapatite/PLA/gelatin with a nanofibrous porous structure by combining homogenization, 
freeze-drying, and thermal treatment approaches. A derived peptide from the bone morphogenetic 
protein 2 (BMP-2-derived peptide) was then immobilized onto the surface of the fibrous scaffold via 
polydopamine. In vitro studies demonstrated the capacity of the altered scaffolds to instigate the 
alkaline phosphatase activity of bone mesenchymal stem cells and the gene expression related to 
osteogenic differentiation. In vivo examinations using a rat cranial bone defect model confirmed this 
scaffold ability to induce bone formation within the defects (Figure 4) [171]. Blends of PLLA and 
gelatin have been tested as well to produce fibrous scaffolds with β-cyclodextrin grafted with nano-
hydroxyapatite and loaded with simvastatin, a known instigator of osteoblasts viability and 
differentiation. Data collected showed these nanostructured scaffolds to significantly increase the 
production of alkaline phosphatase, mineralization, osteogenic gene expression and bone 
regeneration, providing definitive proof of the potential of fibrous, porous biodegradable constructs 
for bone substitution/repair [172]. 
 
Figure 4. Masson’s trichrome-stained images of the newly formed bone within the repaired tissue 
eight weeks after surgery, using scaffolds made of PLA/gelatin (GEL), nano-hydroxyapatite 
(nHA)/PLA/GEL and nHA/PLA/GEL/BMP-2 peptide (-PEP). Red arrows indicate new bone, green 
arrows indicate host bone and black arrows indicate residual scaffolds. Residual scaffolds were all 
clearly filled with intercellular collagen fibers stained blue, and the newly formed bone tissue was 
dark blue because of the existence of abundant and compact collagen. New bone regenerated in the 
nHA/PLA/GEL-PEP group existed both in the middle and limbic of the defects (used with permission 
from [171]). 
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4.6. Cartilage 
The articular cartilage can tolerate intensive and repetitive physical stress with great ease. 
However, it possesses a limited capacity to heal even the most minor injuries. This happens because 
of the reduced availability of chondrocytes, which are embedded in the dense extracellular matrix of 
the articular surface restricting their mobility, and absence of progenitor cells in the proximities of 
the wounded sites. In addition, the articular cartilage is an avascular, aneural, alymphatic tissue that 
only contains chondrocytes, which reduces its self-healing capacity [173]. The use of three-
dimensional biodegradable scaffolds engineered with chondrocytes or progenitor cells has been seen, 
for many years, as an alternative to the limited success of the multiple surgical techniques available. 
In fact, Freed et al. demonstrated just that, by engineering cartilage implants from PGA fibrous 
scaffolds seeded with rabbit articular chondrocytes. These constructs were implanted as allografts on 
adult rabbits to repair knee joint defects. Cartilaginous repair was observed after six months of 
implantation. Compared to PGA alone, the cell-seeded PGA scaffolds improved the chondrocytes 
columnar alignment, the reconstitution of the subchondral plate, the spatial uniform distribution of 
glycosaminoglycans, and the bonding of the repair tissue to the underlying bone [174]. In a similar 
study, Li et al. evaluated the cell-seeded nanofibrous PCL scaffold regenerative properties in swine 
models. PCL constructs were seeded with allogeneic chondrocytes or xenogeneic human 
mesenchymal stem cells to repair iatrogenic, full-thickness cartilage defects during a six-month 
implantation period. In the end, the scaffolds seeded with mesenchymal stem cells were shown to 
regenerate hyaline cartilage-like tissue and to restore a smooth cartilage surface whilst maintaining 
the highest equilibrium of compressive stress, while the chondrocyte-seeded constructs produced 
mostly fibrocartilage-like tissue with a discontinuous superficial cartilage contour [175]. More 
recently, co-cultures of articular chondrocytes and mesenchymal stem cells were seeded onto 
electrospun PCL scaffolds with the purpose of repairing osteochondral defects in the trochlear groove 
of Lewis rats. After twelve weeks of implantation, hyaline-like cartilage tissue was found on the co-
cultured scaffolds, while the bare PCL formed fibrocartilage, which cannot support the original 
cartilage function and deteriorates rapidly. It was also shown that both chondrocyte samples and co-
cultures generated an equal level of cartilage repair, demonstrating their potential in vivo [176]. Still, 
the repaired tissue revealed inferior mechanical properties. Considering this, Kim et al. proposed the 
production of PCL/hyaluronic acid fibrous scaffolds loaded with transforming growth factor-β3 for 
cartilage repair of microfractures in a large animal model such as the minipig. After twelve weeks of 
implantation in vivo, the loaded scaffolds improved histological scores and increased type 2 collagen 
content and the overall mechanical performance [177]. Core-shell nanofibrous scaffolds were 
fabricated to encapsulate bovine serum albumin and the recombinant human transforming growth 
factor-β3 (rhTGF-β3) for tracheal cartilage regeneration. PLLACL was combined with collagen to 
generate the shell portion of the fibers. In vitro testing revealed that rhTGF-β3 could be released at a 
sustained and steady pattern without losing its biological activity. The rhTGF-β3-loaded scaffolds 
were seen to promote the chondrogenic differentiation of mesenchymal stems cells derived from 
Wharton’s jelly of human umbilical cord (Figure 5) [178]. Chitosan-based composite nanofibers 
containing graphene oxide (GO) have also been produced and their potential for cartilage 
regeneration evaluated. Due to its transport properties, allied with its flexibility and the one-atomic-
thickness two-dimensional structure, GO has been pointed out as exhibiting very good 
biocompatibility because of the presence of abundant oxygen functionalities [179]. Tensile strength 
experiments revealed that the incorporation of GO increased the mechanical properties of nanofibers. 
At concentrations of 6 wt%, GO appears to generate a highly biocompatible environment conducive 
with ATDC5 cells (an excellent in vitro cell line model for skeletal development) proliferation [180]. 
Surface modification of gelatin can provide a new generation of biopolymers and fibrous biotextiles 
with chemical, mechanical and biological properties desirable for cartilage tissue engineering. Agheb 
et al. proposed functionalizing gelatin with tyrosine protein and 1,2,3-triazole ring. In vitro cell 
culture studies demonstrated the electrospun engineered protein scaffold to support attachment and 
growth of cells while maintaining their viability. The results also showed that cross-linked nanofibers 
could be considered excellent matrices for chondrocyte adhesion and proliferation in cartilage tissue-
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engineering applications [181]. The former in vitro and in vivo studies verified that spinning 
strategies may allow novel layered scaffolds to be constructed that simultaneously and effectively 
deliver growth factors and fulfill cell migration in a controlled manner to promote tissue 
regeneration. 
 
Figure 5. Chondrogenic differentiation of mesenchymal stem cells derived from Wharton’s jelly of 
human umbilical cord on two different nanofibrous scaffolds, the PLLACL and collagen, here referred 
to as PC; and the PLLACL, collagen and rhTGF-β3, here named PC@rhTGF. (a) Real time-qPCR 
analysis of chondrogenic markers SRY-box transcription factor 9 (So × 9) and collagen type II (COL2) 
after culturing for 14 days (n = 3, * P < 0.05). (b) Histological staining of glycosaminoglycans 
synthesized by the mesenchymal stem cells derived from Wharton’s jelly of human umbilical cord 
with Toluidine and Safranin O after culturing for 21 days (used with permission from [178]). 
4.7. Ligament 
Ligaments are short bands made of strong, flexible, dense connective fibrous tissue found in 
between bones and responsible for joint movement, stability and load transfer. They are mainly 
formed of oriented bundles of collagen fibers. Depending on our daily activities, the ligaments of 
some joints may be subjected to greater strain than others, making them more prone to injury. It is 
clear that the ligaments from knees or legs are subjected to added strain due to body weight and may 
suffer more serious consequences. In fact, one of the most common ligament ruptures occurs at the 
anterior cruciate ligament (ACL), which connects the femur to the tibia and acts as a main stabilizer 
of the knee [182]. Rupture of the ACL results in abnormal joint kinematics and often leads to 
irreversible damage, as it does not heal naturally and requires surgical intervention [183]. Spinning 
techniques associated with tissue engineering tools offer new alternatives for ACL treatment by 
means of biodegradable, fibrous scaffolds with or without seeded cells. The ideal scaffold must 
provide high mechanical strength at the initial moments of implantation and gradually lose it, 
degrading as new tissue is formed [184]. 
Ouyang et al. prepared seven different biodegradable scaffolds, using a solvent spin-casting 
technique, from PCL, PDLA, PLLA, PLGA and mixtures of PLA/PCL and studied the adhesion, 
proliferation and morphology of rabbit ACL cells and bone marrow stromal cells. Data revealed that 
high-molecular-weight PLGA scaffolds were more likely to allow cells to attach and proliferate and 
to promote cell expansion [185]. On the contrary, Lu et al., using the same polymers PGA, PLLA and 
PLGA engineered as three-dimensional braided, fibrous, interconnected scaffolds, established PLLA 
as the most suitable substrate (between the tested samples) for ACL tissue engineering. They 
observed the PLLA scaffolds pre-treated with fibronectin to maintain their structural integrity and 
mechanical performance over time. Primary rabbit ACL cells were also able to attach efficiently on 
Antibiotics 2020, 9, 174 21 of 40 
these substrates and, thus, enhance the long-term matrix production [186]. Recent studies have also 
shown electrospun PCL scaffolds as good candidates for in vivo ACL reconstruction of a rodent 
model. After two, six and twelve weeks of implantation, Petrigliano et al. demonstrated gradual 
infiltration of collagen in both the bone tunnel and intra-articular regions of the scaffold, together 
with the increase in failure load and stiffness over time [187]. In turn, Leong et al., by incorporating 
fibroblast growth factors and human foreskin fibroblasts within the PCL grafts matrix, provided 
evidence of the fibrous constructs’ excellent healing and regenerative potential. Indeed, after 16 
weeks of implantation on athymic rat models, infiltration of the grafts with cells and aligned collagen 
deposition with minimal inflammatory reaction were observed. Here too, the mechanical 
performance was improved over time [188]. PLCL and silk fibroin have been processed by 
electrospinning in three ways—random nanofibers, aligned nanofibers and aligned nanoarrays—and 
studied for their mechanical performance in light of ligament requirements. The Young’s modulus of 
the aligned nanoarrays was inferior to the other configurations; however, it provided larger pores 
and enough space for cell infiltration, which yielded improved cell proliferation for up to 28 days of 
culture. The aligned nanoarrays achieved a balance between porosity and mechanical properties 
highly desirable in tissue engineering [189]. 
For many years, the natural choice for ACL reconstruction fell on collagen-based fiber scaffolds. 
However, their mechanical strength and degradation rates were not easily controlled [190]. Lately, 
silk and collagen blends have been prepared to mimic the components of the ligament and thereby 
accelerate regeneration. Implantation in rabbits demonstrated that cell infiltration increased over 
time on these constructs and that more fibroblast-like cells were found in their core. Compared to 
autografts, silk/collagen fibrous scaffolds enhanced the most tendon-bone healing and instigated 
trabecular bone growth into the scaffold. In the end, their potential for clinical applications was 
established [191]. A hybrid scaffold composed of degummed knitted silk microfibers coated with 
bioactive basic fibroblast growth factor (bFGF)-releasing electrospun PLGA fibers was produced by 
Sahoo et al. In vitro testing demonstrated the ability of rabbit bone marrow mesenchymal stem cells 
to grow on these scaffolds and the bFGF to stimulate cell proliferation and gene expression, 
increasing collagen production and, hence, the fibrous construct mechanical properties [192]. 
5. Drug Delivery Systems 
In the quest for efficient drug delivery systems, by means of systemic and topical routes, 
biotextile structures have been fashioned in a variety of formats, resembling interconnective tissues, 
the extracellular matrix and even organs. In fact, over the last fifty years, potential administration 
routes via biotextiles have gone from wounds, burns and dermatosis, the most common, to systemic 
diseases, implantable devices and nanoencapsulation [193]. Drug delivery systems based on 
biotextiles can now sustain local release, control deliverance, target cell/microorganism strains or 
biomolecules, and even boost smart release via local stimuli by means of topical, transdermal and 
implantable administration. In recent years, electrospun fibers designed to entrap biologically active 
molecules have proven efficient in protecting affected areas against pathogens this way, preventing 
microbial colonization and accelerating healing. The main requirement for a drug delivery system to 
be considered as an effective tool is its capacity to maintain the pharmacologically effective 
therapeutic drug levels for prolonged periods of time while still allowing “dosing-on demand” [194]. 
Innovative manufacturing techniques are emerging to design fibrous scaffolds with proper textured 
fiber meshes to achieve specific performances in different biomedical environments. Indeed, different 
strategies have been optimized to incorporate molecular species into polymer-based solutions either 
by direct (e.g., co-axial spinning) or indirect (e.g., co-spinning) encapsulation [1,195]. Drug-release 
profiles are mainly dependent on the physical–chemical properties of the polymer. As such, hybrid 
architectures made of natural and synthetic materials are also being engineered with the purpose of 
offering delivery platforms with controlled degradation rates, responsive to local stimuli, for targeted 
biomolecule release. Examples of biotextile-based drug delivery systems are explored in the 
following sections. 
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5.1. Topical 
Topical administration of specialized therapeutic agents, such as antibiotics, plant extracts, 
antimicrobial peptides or proteins and nanoparticles, is a favored route for a localized action. This 
strategy is preferred in many cutaneous, eye and vaginal disorders because of its convenience, easy 
application, affordability, minimum toxicity, superior physiological and pharmacological responses, 
enhanced drug bioavailability and, since it requires non-invasive procedures, painlessness for the 
users. Topical systems are highly desirable as potential substitutes for systemically administered 
drug therapies, by minimizing side effects associated with drug dosage and off-target action. The 
most challenging aspect of designing such a therapeutic system relates to the delivery platform from 
which an optimal biomolecule concentration can remain active while being delivered for an 
appropriate time period [196,197]. Even though they are not as challenging as in systemic routes, 
topical administration still must overcome barriers that may limit the bioavailability of drugs and its 
deliverance at the effective site. Local infections masking the affected area are known to inhibit the 
action of therapeutic agents used to stimulate anti-inflammatory responses or cell growth and 
proliferation [198]. 
Nanofibrous biotextiles have been described to possess a large surface area capable of efficiently 
binding and delivering hydrophilic and hydrophobic drugs. Furthermore, their release rate can be 
tuned to meet the specific clinical demands of the affected area by modulating the fibers' diameter, 
morphology, structural organization, porosity, drug protection (direct or indirect loading, namely 
co-axial or co-spinning) and content ratio between polymers and drug. Biomolecules can also be 
functionalized at the surface of the nanofibers by physical or covalent binding for a faster delivery 
[39]. 
Highly infected and chronic wounds are some of the clinical pathologies where topical 
administration of drugs via biotextile platforms are the most frequent and viable. Here, topical 
delivery vehicles can provide therapeutic action directly to the wound bed or the affected area, using 
one- or multiple-agent systems, potentially reducing unwanted side effects. Dual release electrospun 
scaffolds containing an anesthetic, lidocaine, and an antibiotic, mupirocin, were produced from PLLA 
using a dual-spinneret electrospinning apparatus. Their release rate was followed, revealing 
discrepancies between biomolecules: while lidocaine displayed an initial burst of 80% of its weight 
in the first hour, mupirocin only released 5%, therefore experiencing a more sustained release for 
effective antibacterial action. By comparing with single-spinneret electrospun mats, drug release 
kinetics was seen to alter due to the competitive behavior between molecules and the different 
polymer interactions generated [199]. Topical administration of levothyroxine, a synthetic hormone 
that stimulates lipid metabolism and induces lipolysis, has been reported to reduce deposits of 
adipose tissue in the skin. At high concentrations, however, potential systemic effects may be 
unleashed. To overcome this, nanofibrous textiles of blends of PVA and poly-N-isopropylacrylamide 
(PNIPAM) were proposed for sustained topical delivery of this hormone. Data reported the ability of 
the polymeric biotextile to sustain the release and penetration of levothyroxine within the skin while 
maintaining its effectiveness for longer periods and minimizing systemic adsorption [200]. PVA has 
also been combined with poly(vinyl acetate) (PVAc) to form nanofibers loaded with ciprofloxacin 
hydrochloride (CipHCl), a quinolone antibiotic used to treat a variety of bacterial infections. Here, 
too, both the kind of polymer and the amount of drug loaded greatly affected the degree of swelling, 
weight loss, and initial burst and rate of drug release. Pristine PVAc fibers were capable of sustaining 
release of 50% of the drug for 80 days, whereas the PVA nanofiber mats released the drug within 3 
days. Blending the two polymers allowed for a convenient rate and period of drug release to be 
attained, optimal to fight skin infections [201]. Antimicrobial fusidic-acid-loaded electrospun PLGA 
ultrafine fibers have also been examined for their potential in treating infected wounds under 
dynamic conditions. It was seen that the engineered constructs allowed a progressively faster release 
of bioactive fusidic acid, eradicating planktonic bacteria and considerably suppressing biofilm 
formation. However, findings point out the risk of wound reinfection and microbial resistance from 
using non-medicated or inadequately medicated bioresorbable fibrous dressings [202]. The same 
recommendations were made by Alhusein et al. while reporting the release of tetracycline 
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hydrochloride (tetHCl) from a triple-layered electrospun matrix, made of poly(ethylene-co-vinyl 
acetate) (PEVA) at the center, sandwiched between two layers of PCL [203]. The engineered topical 
scaffold was found very effective in entrapping the antibiotic and promoting their efficient timely 
local release, inhibiting the growth of a panel of bacteria, including clinical isolates. PCL and 
hyaluronic acid have been conjugated with epidermal growth factors via emulsion electrospinning, 
revealing significant synergistic effects that contributed to cell proliferation and infiltration, 
ultimately leading to an enhanced regeneration that culminated in fully functional skin. Moreover, 
an up-regulation of wound-healing-related genes like collagen I, collagen III and TGF-β was also 
reported [204]. Even though blend emulsion electrospinning has been an option in many studies, 
there are others that defend this strategy to destroy the bioactivity of proteins or to make the 
electrospun dope highly unstable [205]. Using bovine serum albumin as a carrier protein, Peh et al. 
proposed a simultaneous blend-spun of Vitamin C, Vitamin D3, steroid hormone hydrocortisone, 
insulin, thyroid hormone triiodothyronine, and epidermal growth factors into PLGA-collagen 
nanofibers. The engineered strategy allowed for a target-release of each biomolecule, with Vitamin C 
facilitating collagen I secretion by fibroblasts, insulin potentiating adipogenic differentiation and 
Vitamin D3, steroid hormone hydrocortisone, insulin, thyroid hormone triiodothyronine and the 
epidermal growth factors stimulating skin fibroblast and keratinocytes proliferation [206]. Aside 
from infected wounds, topical skin administration of biomolecules has also been employed in the 
treatment of other disorders, namely keloids. These are fibroproliferative lesions that occur at areas 
of cutaneous injury. They are benign but often cause pain, tenderness, pruritus and paresthesias. Li 
et al. proposed a new strategy to treat these conditions by co-delivering dexamethasone and green 
tea polyphenols at the affected area using PLGA nanofibers. The engineered biotextile was 
characterized as multi-functional by including capacities to maintain a moist environment, resisting 
bacterial infection and controlling drug release. After a three-month period of treatment, these 
PLGA/dexamethasone/green tea polyphenols fiber meshes were found to significantly increase the 
degradation of collagen fibers in keloids compared to the traditional methods [207]. Another benign 
skin condition of long duration that affects most people during adolescence is acne. Current strategies 
to treat acne resort to antibiotics and biomolecules delivered to the skin in the form of pills, ointments, 
gels or soaps. Most recently, Khoshbakht et al. proposed the fabrication of tretinoin-loaded PCL 
nanofibrous mats as a potential anti-acne patch. Electrospun nanofibers showed a prolonged release 
of tretinoin, which was then reflected in a superior antibacterial action. Additionally, the drug-loaded 
construct showed inherent stability under various storage conditions at room and fridge-preserving 
temperatures, anticipating that the easy fabrication, low costs and dosing frequency of this strategy 
may offer a new therapeutic platform for treating acne disorders [208]. 
Electrospun nanofibers have also been applied in eye diseases. One of the most challenging 
issues in treating eye diseases is the very short residence time of the drug. Most drugs are eliminated 
within a few seconds due to the poor capability of the eye to accommodate additional liquids. As 
such, alternative drug delivery systems have been engineered in the form of fibers and gels. 
Voriconazole, a triazole antifungal agent with low aqueous solubility, good oral bioavailability, 
acceptable tolerability and promising activity against resistant fungal species and fungal isolates 
associated with keratitis, has been incorporated into polyvinyl alcohol (PVA)/hydroxypropyl-β-
cyclodextrin (HPβCD)-blended nanofibers for efficient ophthalmic delivery. Drug loading was 
significantly enhanced by the presence of HPβCD. Compared with a voriconazole free state solution, 
the nanofibers significantly prolonged the antibiotic half-life and increased its bioavailability in rabbit 
tears. Further, no obvious signs of irritation were detected after application in the conjunctival sac 
[209]. Dendrimer-based nanofibers made of polyamidoamine have also been examined as topical 
delivery vehicles for the glaucoma drug brimonidine tartrate. These systems were considered non-
toxic and did not cause ocular irritation in animal tests using a normotensive rat model. Intraocular 
pressure response also improved with daily dosing [210]. Recently, Göttel et al. proposed a system 
based on gellan gum/pullulan electrospun nanofibers shaped into curved geometries and capable of 
turning into a gel upon administration. A clear prolongation of the fluorescein residence time 
compared to conventional eye drops was confirmed using the developed in situ gelling system [211]. 
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Grimaudo et al. also showed the ability of hyaluronic acid nanofibers to work as a dual delivery 
system for ferulic acid, an antioxidant, anti-aging, anti-inflammatory, neuroprotective and hemato-
protective agent, and ε-polylysine, a water-soluble, biodegradable antimicrobial peptide active 
against bacteria, fungi and yeast. The engineered multi-action system demonstrated a controlled 
release of the biomolecules within the first hour of contact without inducing a cytotoxic response, 
and with an effective action against relevant microbial species prevalent in chronic ocular diseases 
[212]. Once again, the value is proven of nanofiber-based delivery systems as alternatives to aqueous 
drug-based solutions to treat ocular-related disorders. Still, topical formulations are less effective in 
treating retinal inflammatory diseases. As such, Singla et al. proposed the development of 
preservative-free fluocinolone acetonide-loaded PCL nanofibers. This corticosteroid is used in 
dermatology to reduce inflammation and relieve itching. Here, both plasma and ocular kinetics 
supported the therapeutic utility and target-site deliverance of the fluocinolone acetonide, without 
systemic distribution. This single application maintains the therapeutic window for longer periods, 
thus ensuring higher patient adherence and compliance. PCL was once again highlighted as a 
promising drug carrier. Apart from the already-mentioned features, PCL gained popularity as a 
potential alternative for human amniotic membrane by promoting adhesion, supporting cell 
proliferation and infiltration to form a three-dimensional corneal epithelium [213]. 
A great number of vaginal disorders arise from sexually transmitted infections. For that reason, 
multipurpose prevention technologies (MPTs) that simultaneously prevent sexual diseases and 
unintended pregnancy remain a global health priority. Combining chemical and physical barriers in 
one potential therapeutic formulation has been a great challenge. Ball et al., using FDA-approved 
polymers, polyethylene oxide (PEO) and PLLA, produced nanofiber meshes with tunable fiber size 
and controlled degradation kinetics to enable the topical release of multiple agents against HIV-1, 
HSV-2, and sperm at the vaginal mucosa. Data reported the capacity of these electrospun biotextiles 
to inhibit HIV-1 infection and to physically obstruct sperm penetration, providing a physical 
coverage for both the vaginal epithelium and cervix. Here, multiple non-hormonal chemical 
contraceptive alternatives were screened, uncovering the potential of glycerol monolaurate to inhibit 
sperm motility and viability in a dose-dependent manner [214]. Formulations to co-deliver more than 
one therapeutic agent in vaginal disorders or as contraceptive agents are very frequent. Biotextiles 
made of PVA-based nanofibers have been fashioned and loaded with tenofovir and levonorgestrel (a 
contraceptive progestin) using a production-scale electrospinning equipment. The engineered fabrics 
showed good drug association efficiencies and a reasonably high drug loading, the release rate of 
which could be modulated by changing the fiber architecture’s polymer/drug ratio. In vitro studies 
demonstrated this system low cytotoxicity and the ability to sustain the anti-HIV activity of tenofovir 
[215]. Huang et al. formulated a therapy in which the polymeric drug delivery platform would release 
specialized antiretroviral drugs responsible for fighting sexually transmitted diseases only upon 
contact with sperm. Cellulose acetate phthalate (CAP)-based nanofibers were produced by 
electrospinning and loaded with etravirine and tenofovir disoproxil fumarate agents. Because of the 
CAP pH sensitivity, fibers were insoluble in simulated vaginal fluid at pH 4.2 but dissolved quickly 
upon contact with human semen at pH 7.0–8.5, thus releasing the drugs. CAP also possesses anti-
HIV activity, which may include additional effects to this therapeutic topical strategy [216]. Current 
approaches also include the combination of nanofiber biotextiles functionalized with nanocarriers 
containing therapeutic biomolecules. These strategies have been recently proposed due to the poor 
retention and extensive leakage of nanocarriers (in the form of nanoparticles or nanocapsules) in 
topical vaginal administration. Such an example is the research of Krogstad et al., in which a 
nanoparticle-releasing nanofiber delivery platform was developed by combining mucoadhesive 
fibers for better retention in the vaginal tract, and PEGylated nanoparticles loaded with etravirine, a 
topical microbicide for HIV prevention, that diffused quickly through the mucus. This composite 
formulation was seen to provide 30-fold greater retention of nanoparticles in the reproductive tract 
compared to aqueous suspensions. Further, the functionalized nanoparticles displayed sustained and 
higher etravirine concentrations up to 7 days of culture, demonstrating the efficacy of single-dose 
topical therapies [217]. 
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5.2. Transdermal 
Transdermal applications of bioactive dressings aim at transporting drugs into the bloodstream 
by penetrating the skin barrier. In the past, only a few drugs were approved as transdermal patches, 
like steroid hormone and nicotine, due to their bioavailability [218,219]. In recent years, there has 
been an increased interest in transdermal delivery systems as a new approach for drug 
administration. Contrary to systemic products, transdermal patches can provide a sustained release 
of a drug from the device into the skin, are non-invasive systems, avoid gastric irritation and 
bypassing the first-pass metabolism, and are relatively low toxic. Another benefit of using biotextile 
transdermal delivery systems is the ability to very easily and quickly stop a therapeutic treatment in 
case of adverse effects [220,221]. 
Different transdermal delivery systems have been designed following the evolution of polymer 
science [222]. Natural, synthetic and hybrid polymers are the backbone of transdermal delivery 
systems as they allow to control the release of drugs through the intact skin [223]. Frequently, 
polymers are processed in the form of nanofibers and used as delivery platforms to treat difficult 
wounds, both mechanically and chemically [224]. Aside from entrapping bioactive molecules 
necessary to induce healing or fight infections, they also absorb excess exudates and facilitate oxygen 
permeability via their large surface area and interconnected open pore structure, respectively. 
Further, the nanofibrous constructs morphology and chemical composition may also condition the 
loading capacity and release profile of the drugs. Currently, there are even smart strategies that 
release drugs in response to the environment ion or enzyme concentrations and pH levels [221]. 
The absence of several types of vitamins in the human body can lead to severe health problems 
ranging from megaloblastic anemia to Parkinson’s disease [225,226]. In an attempt to improve 
transdermal delivery of Vitamin B12, Vitamin E and Vitamin A and surpassing more effectively the 
skin barrier, Madhaiyan et al. [219] and Taepaiboon et al. [227] explored alternative routes based on 
nanofibrous constructs made of PCL and cellulose acetate, respectively. Vitamin B12 (cobalamin) is 
a water-soluble vitamin necessary for red blood cell formation, neurological function and DNA 
synthesis and is naturally present in some foods [226]. In turn, Vitamin E and Vitamin A acid are 
lipid-soluble substances that prevent skin disorders and have antioxidant properties [227]. Vitamin 
B12-loaded PCL electrospun fibers were surface-modified by plasma treatment to increase the period 
of fiber degradation, loading capability and hydrophilicity, thereby enhancing the vitamin release 
rate above untreated PCL. The plasma-treated PCL transdermal patch allowed a release of 34% of 
vitamin B12 per day, equivalent to 340 mcgs, the daily requirement in cases of vitamin deficiency. 
The increased hydrophilic nature of the patch facilitated release because of water-sorption-mediated 
drug desorption [219]. Similarly, mats made of electrospun cellulose acetate loaded with vitamin E 
(5 wt%) and vitamin A acid (0, 5 wt%) were produced by eletrospinning. As expected, due to the low 
stability of Vitamin A acid, cellulose acetate fibers could incorporate more Vitamin E (≈83%) than 
Vitamin A acid (≈45%). Still, in both cases, their encapsulation efficiency was confirmed. Subsequent 
studies of drug releasing in a acetate buffer solution showed that fibers were stable and capable of 
maximum release of Vitamin E and Vitamin A acid within 24 and 6 h, respectively, highlighting this 
biotextile as an effective transdermal drug delivery system [227]. 
The local delivery of drugs is preferred to systematic administration in wounds as it accelerates 
healing by speeding the healing phases in acute injuries and by administrating more effectively 
antimicrobial agents capable of preventing or fighting infections. Drug-loaded biotextiles containing 
antibiotics, anti-inflammatory substances and biomolecules are an excellent alternative to produce 
functionalized biological and biochemical dressings for wound therapies. Both synthetic and natural-
origin polymers, like PVA and chitosan, combined with antibiotics or biomolecules have shown great 
performance in accelerating the rate of healing and controlling drug release, making them suitable 
for transdermal drug systems [228,229]. Kataria et al. produced biodegradable PVA and sodium 
alginate modified by active loading with ciprofloxacin, a fluroquinolone antibiotic (agents commonly 
applied against microorganisms present in skin infections) to prevent wound infections. Data 
reported the nanofiber transdermal patch to follow the Higuchi and Korsmeyer–Peppas model for 
drug release, with a controlled, sustained delivery with time. Once again, loaded patches were more 
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effective in controlling infections, accelerating healing and promoting re-epithelialization (in vivo) 
than the free state antibiotics or unloaded patches [228]. The same was reported by Mendes et al. 
when mixing chitosan with phospholipids to generate electrospun hybrid nanofibers and posteriorly 
loading the structure with a variety of substances, including curcumin (an antioxidant, anti-
inflammatory agent and an inhibitor of tumorigenesis and metastasis), diclofenac (anti-inflammatory 
agent) and Vitamin B12. Here too, the hybrid biotextile presented great stability in physiological 
environment due to chemical interactions established between the natural polymer and the 
biomolecules, suitable biocompatibility and a controlled, sustained release of all tested substances 
[229]. 
Curcumin is a naturally occurring poly-phenolic compound with innate antimicrobial action 
and a broad range of biological functions, including anticancer, antioxidant, anti-infective, angiogenic 
and anti-inflammatory activities. However, its in vivo low bioavailability and fragile stability 
demands suitable carrier vehicles to be used to sustain its action and continuous release towards 
affected areas. In that sense, Ranjbar-Mohammadi et al., by producing curcumin-loaded PCL/gum 
targacanth nanofibers for wound healing disclosed their ability for applications in diabetic 
conditions. Indeed, after 15 days of culture, pathological studies demonstrated the markedly fast 
wound closure promoted by the engineered biotextiles, with well-formed granulation tissue 
dominated by fibroblast proliferation, collagen deposition, complete early regenerated epithelial 
layer and formation of sweat glands and hair follicles (Figure 6) [230]. Ravikumar et al., using a CAP 
nonwoven template, achieved similar results, confirming the liberation of curcumin in a controlled 
manner via transdermal delivery [231]. The same was observed by Rramaswamy et al. using 
tetrahydro curcumin loaded onto PCL/PEG hybrid formulations processed in the form of electrospun 
hybridized transdermal patches. They also concluded that drug diffusion in such systems follows 
Higuchi’s model diffusion mechanism [232]. 
In recent years, the world population has been facing a dominant problem that prevails in most 
developed countries and affects millions of people, namely obesity [233]. Ariamoghaddam et al., 
using a blend of PVA/gelatin loaded with curcumin, verified this natural extract as a potent anti-
obesity agent and engineered a transdermal delivery patch to decrease the sub-cutaneous volume of 
adipose tissue in obese rats. Curcumin-loaded patches were applied in the abdomen region of obese 
rats for 6 weeks. Afterward, the rats were exposed to magnetic resonance imaging and compared to 
control groups consisting of normal-diet and high-calorie-diet rats. Results confirmed that these 
modified PVA/gelatin-based biotextiles effectively deliver curcumin biomolecules through the skin 
and that these patches were efficient in decreasing the volume of adipose tissue within the tested 
subjects by 4% to 7%. Once again, the capacity of bio-synthetic hybrid polymers was demonstrated 
to generate sustainable drug-loading nanofiber systems, with optimal transdermal delivery, as 
alternatives to conventional systemic therapies [234]. 
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Figure 6. Evidence of accelerated wound closure in diabetic rat models (in vivo testing) promoted by 
curcumin-loaded biotextiles (adapted with permission from [230]). 
5.3. Implantable 
Implantable drug delivery systems are designed to store and deliver small, precise doses of 
therapeutic drugs or medicines into the bloodstream or directly to specific tissue sites. The major 
advantages of these systems include targeted local delivery of the drug at a constant and 
predetermined rate, thereby minimizing dose required and potential side effects while improving 
therapeutic efficacy [194]. 
Implantable drug delivery systems essentially consist of a micropump that contains a reservoir 
in which the pharmaceutical drug in gaseous or liquid form is stored, an actuator release or pump 
mechanism, inlet and outlet valves, and in some cases a catheter to directly deliver the drug to a 
target site. Alternatively, the drug can be blended with the implantable materials and then, by using 
compression- or injection-molding techniques, generate a device with a pre-defined architecture. 
However, controlling of the structure and the internal architecture of the system has proven a real 
challenge. Further, in many instances, the drug becomes inaccessible or loses its activity. Biotextiles 
have been proposed as novel strategies for the development of implantable drug delivery systems 
with applications in long-term diseases, including cardiovascular, tuberculosis, diabetes, cystic 
fibrosis, glaucoma, cancer, etc. [235]. Indeed, in Section 4, some of those implantable systems have 
already been analyzed and examples of bioactive molecules or antibiotics released from biotextiles 
have been explored. Still, one of the most important applications of fibrous implantable drug delivery 
systems remains to be disclosed, namely the detection and treatment of cancer. 
Polymer-based systems have raised much attention in the last few decades as a means of 
achieving high therapeutic concentrations of chemotherapy to the site of malignant diseases in cancer 
patients by implanting drug-loaded systems intra-tumorally or in areas adjacent to the cancerous 
tissue. Most of these devices are fashioned from biodegradable polymers to circumvent a second 
surgery for device removal, in already debilitated patients, and to avoid a chronic foreign-body 
immune response. The development of such devices is guided by the desire to improve overall 
survival and quality of life by patients [236]. 
Gao et al. proposed the incorporation of 5-fluorouracil, a hydrophilic anticancer drug more 
effective when administered at lower doses for longer periods, onto PLLA fibers. The fabrication 
process selected was wet-spinning. The drug release rate was regulated by optimizing the processing 
parameters, such as drug content, polymer concentration, nonsolvent composition and extrusion 
flow rate. Most of the drug was encapsulated into the PLLA bulk fibers, achieving good-term release 
profiles with small initial burst, desired for cancer treatments [237]. This drug, together with 
oxaliplatin, is currently a mainstay of adjuvant chemotherapy in colorectal cancer patients. However, 
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systemic delivery exposes not just tumor cells but other body organs to their toxicity. Moreover, 
oxaliplatin-induced peripheral neuropathy remains a main concern to the use of this drug. As such, 
these two drugs have been loaded onto PLLA electrospun nanofibers and their effects examined 
when directly exposed to human colorectal cancer HCT8 cells (in vitro) and colorectal CT26 tumor-
bearing mice (in vivo). In both situations, the drug-loaded PLLA fibers displayed antitumor efficacy 
in a time-dependent manner, sustaining drug release for longer, and suppression of tumor growth, 
which prolonged the animal’s survival [238]. Oxaliplatin has also been tested in combination with 
dichloroacetate, a metabolic modulator, using a dual drug-loaded multilayered PLLA system. This 
strategy was proven to be effective in sustaining the local release and action of the drugs in a time-
programmed manner. Moreover, the synergistic effect between the two drugs was demonstrated to 
prevent local cancer recurrence following surgery [239]. 
Doxorubicin (DOX) is an anthracycline antibiotic with antineoplastic activity, commonly 
applied as chemotherapy medication to treat a variety of cancers (breast, bladder, lymphomas, 
leukemia, etc.). Systemic administration of this drug is associated with severe toxicity in healthy 
tissues, limited distribution, low resection rates and, overall, poor patient survival. To overcome these 
limitations, Yang et al. developed a localized, implantable drug delivery device made from 
hydrophobic DOX-encapsulated active-targeting micelles assembled from a folate-conjugated PCL-
PEG copolymer. These micelles were then incorporated in a PVA matrix, forming the core of co-axial 
electrospun nanofibers surrounded by gelatin. The engineered nanocarrier delivering system was 
seen to reduce drug dose requirements, frequency of administration and chemotherapeutic-related 
side effects while maintaining an effective therapeutic action against artificial solid tumors [240]. 
Similar observations were made by loading DOX onto mesoporous silica (MSNs) nanocarriers and 
then by incorporating those structures into PLLA nanofibers. Loaded scaffolds were successfully 
fashioned, exhibiting good nanocarrier distribution and improved thermal stability. More 
importantly, they allowed for high doses of DOX to be loaded, sustaining its release for longer 
periods than MSNs- or DOX-free counterparts, thus increasing their in vitro antitumor efficacy 
without compromising the viability of surrounding healthy cells [241]. In a following study, Liu et 
al. produced a biotextile in which the DOX was loaded directly onto PLLA without using a ceramic 
nanocarrier. Secondary hepatic carcinoma mice models were prepared by injecting murine mammary 
carcinoma EMT6 cells into the left hepatic lobe and into the portal vein of Balb/c mice. DOX-loaded 
PLLA mats were then used to cover the affected areas. The growth of the nodular secondary hepatic 
carcinomas was significantly inhibited by the prolonged, controlled release of DOX, whereas the 
median survival time of the mice bearing diffuse secondary hepatic carcinomas was increased from 
14 to 38 days. Throughout that time, neither injury to neighboring liver tissues nor systemic adverse 
reactions were observed [242]. To establish an even greater optimal control of drug targeting, Li et al. 
proposed the use of DOX-loaded photoluminescent MSNs modified with a pH-sensitive 
polydopamine “gatekeeper” for quick release and faster uptake by cancer cells. These 
photoluminescent nanocarriers were functionalized at the surface of PCL/gelatin electrospun 
nanofibers modified with photothermal carbon nanoparticles, forming a highly specialized 
implantable biotextile. Compared to drug administrations in the free form, the implant was seen to 
significantly enable a superior cell uptake effect, thus increasing the drug efficacy against tumor cells 
by responding to under-near-infrared irradiation. The photothermal effect of the carbon nanotubes 
weakened the electrostatic interaction between the photoluminescent nanocarriers and the 
PCL/gelatin nanofibers, resulting in the controlled release and, subsequently, internalization of DOX 
for a more effective cancer cell killing action [243]. 
6. Conclusions and Future Perspectives 
The ideal design for tissue engineering devices falls within the features of fibrous constructs 
obtained via spinning techniques. It is generally agreed that biocompatible, biostable, biodegradable, 
porous devices are the most appropriate for both hard and soft tissue repair and substitution. They 
are designed with a fiber-based, highly porous and interconnected architecture that resembles the 
extracellular matrix, creating in this way an environment conducive with cell penetration, adhesion, 
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proliferation and ultimately tissue regeneration. In many cases, the association with biomolecules, 
such as drugs, plant extracts, growth factors, proteins, peptides or essential oils may facilitate this 
task, giving rise to controlled biomolecule delivery systems that not only promote tissue regeneration 
but fight infections as well. 
Among the spinning techniques available for fibrous architecture production for tissue 
engineering or biomolecule delivery applications, electrospinning can be highlighted by the ease of 
process but most importantly by the ability to control in great detail each processing parameter to 
obtain large surface area fibrous structures at the nanometer scale. Biodegradable polymers have 
gained an important status over the years by replacing biostable temporary therapeutic devices, used 
only for substitution, with systems capable of stimulating the body to repair and regenerate while 
degrading at an equal rate. These biodegradable fiber-based constructs are fashioned with desirable 
mechanical strength, structural integrity, large surface area and open pore structure to successfully 
respond to local demands. Loading with biomolecules may ease this process and make the 
integration of the antimicrobial biomaterials quicker and less harmful for the patient. 
Nowadays, biotextiles developed from spinning techniques are in great demand. They combine 
textile technologies with antimicrobial biomaterials to generate vascularized therapeutic devices for 
a variety of applications. Indeed, there are surgical meshes, wound dressings, ligaments and soft 
tissue substitutes currently being tested in clinical trials that are based on the concepts revised in the 
present review. The main challenges related to the application of biotextiles in tissue engineering 
consist of the combination of textile machinery with biomaterials and the advances necessary to 
generate tissues and organs automatically. For instance, the manufacturing process of fibers 
developed from synthetic materials hampers the capacity of cell encapsulation inside the fibers, 
establishing the need for more advanced fiber fabrication techniques; therefore, it is likely that the 
field of tissue engineering will advance towards that direction. Another obstacle relies on the inability 
of implantable fabrics to capture the in vivo mechanic and biological properties of the organs and 
tissues. Indeed, clinical applications of such constructs have demonstrated that in vitro and ex vivo 
analysis results in quite different outcomes than actual real-life conditions. An alternative to address 
this challenge would require the use of fibers from biomaterials with adjustable properties that enable 
the delivery of growth factors or by the application of textile-based tissues on the development of in 
vivo disease models and drug testing platforms. Furthermore, new smart fiber-forming polymers are 
being developed with unique properties, and as soon as they are spun, they may function as 
biosensors, actuators and drug delivery systems responsive to pH, temperature and drug 
concentration. Moreover, with computational capabilities advances, computational approaches can 
be used to better understand the resorption properties and mechanisms by controlling the processing 
parameters and the different chemical compositions. 
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